Journal
CLINICAL INFECTIOUS DISEASES
Volume 65, Issue 8, Pages 1327-1334Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cix559
Keywords
Burkholderia cepacia complex; bacteremia; drug resistance; multidrug resistance; electronic health records.
Categories
Funding
- National Institutes of Health (NIH) through the Clinical and Translational Science Collaborative of Cleveland [UL1TR000439]
- National Institute of Allergy and Infectious Diseases [AI100560, AI114508]
- Cleveland Department of Veterans Affairs, VA Research and Development Office from the US Department of Veterans Affairs Biomedical Laboratory Research and Development Service [BX001974, BX002872]
- Veterans Integrated Service Networks-10 Geriatrics Research, Education and Clinical Center
Ask authors/readers for more resources
Background. Burkholderia cepacia complex (Bcc) are a group of multidrug-resistant gram-negative bacteria rarely reported in patients without cystic fibrosis (CF) or immunocompromising conditions. We investigated Bcc bloodstream infections (BSIs) in a cohort of non-CF patients from the US Veterans Health Administration (VHA). Methods. Using VHA databases, we identified patients with Bcc BSI at facilities nationwide from 1999 through 2015. We ascertained clinical characteristics, treatments, and outcomes and identified factors associated with 30-day mortality in logistic regression analysis. Results. We identified 248 patients with Bcc BSI, who were of advanced age (mean, 68 years), chronically ill, and had severe disease. The most common sources were central venous catheters (41%) and pneumonia (20%). Most cases were hospital-acquired (155 [62%]) or healthcare-associated (70 [28%]). Mortality at 14, 30, and 90 days was 16%, 25%, and 36%, respectively. Trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolones were active against 94% and 88% of isolates, respectively. Susceptibility to ceftazidime and meropenem occurred in approximately 70% of the isolates. The most prescribed antibiotics were fluoroquinolones (35%), followed by carbapenems (20%), TMP-SMX (18.5%), and ceftazidime (11%). In regression analysis, age (OR, 1.06 [95% confidence interval {CI}, 1.02-1.10], per added year) and the Pitt bacteremia score (OR, 1.65 [95% CI, 1.44-1.94], per unit increase) were associated with higher 30-day mortality. Conclusions. In this large cohort of BSIs caused by Bcc, cases were mostly hospital-acquired and we observed high mortality, significant resistance to ceftazidime, and limited use of TMP-SMX. These observations add to our understanding of Bcc infection in non-CF patients and highlight the need for interventions to improve their outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available